In this network meta‐analysis, all third‐gen TKIs outperformed first‐gen TKIs, with no significant differences in efficacy among them for EGFR‐mutated NSCLC in the first‐line setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.